Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Context Therapeutics Inc.NASDAQ: CNTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 39.0% from a year ago
Cash & equivalents stood at $54.53M at the end of Q1 FY2026, down 39.0% from a year earlier and down 17.4% from the prior quarter. Over 3 fiscal years it compounded at +23.0% a year.
Context
- Cash & equivalents amounted to 92.6% of total assets at the end of Q1 FY2026, down 3.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -39.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 66M USD
- Year-over-year change
- -30.1%
- 4-year CAGR
- +7.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66M | -30.1% |
| FY2024 | 2024-12-31 | 94.43M | +553.5% |
| FY2023 | 2023-12-31 | 14.45M | -59.3% |
| FY2022 | 2022-12-31 | 35.5M | -28.5% |
| FY2021 | 2021-12-31 | 49.64M | — |
Cash & Equivalents vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -39.0% is the 4th highest of 11, against a peer median of -52.6%.
- Cash & equivalents amounts to 92.6% of total assets for CNTX, versus a peer median of 31.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M USD | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
IMAImageneBio Inc | Mar 2026 | $76.05M USD | +106.9% | -16.4% | 55.6% |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $54.53M USD | -39.0% | +23.0% | 92.6% | |
| Dec 2025 | $38.35M USD | -51.0% | -21.4% | 68.4% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $34.79M USD | -84.7% | -1.3% | 27.3% |
KLRSKalaris Therapeutics Inc | Mar 2026 | $34.43M USD | -65.9% | +217.7% | 31.4% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Mar 2026 | $5.94M USD | -39.6% | -34.3% | 27.4% | |
| Peer median (excluding CNTX) | — | -52.6% | -8.8% | 31.0% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 49.64M | 35.5M | 14.45M | 94.43M | 66M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (0) | 2.36M | 1.6M | 3.47M | 2.36M |
| Total Current Assets | 51.26M | 37.85M | 16.05M | 97.9M | 68.35M |
| Property, Plant & Equipment (Net) | 0 | 79.54K | 15.52K | 230.78K | 140.07K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 50.39K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 32.75K | 0 | 0 | 0 |
| Total Non-current Assets | 50.39K | 112.29K | 15.52K | 230.78K | 140.07K |
| Total Assets | 51.31M | 37.97M | 16.06M | 98.13M | 68.49M |
| Account Payables | 1.83M | 936.33K | 2.38M | 1.45M | 2.53M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 85.53K | 853.51K | 661.3K | 941.7K | 1.42M |
| Total Current Liabilities | 3.03M | 3.21M | 4.19M | 2.75M | 8.02M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 0 | 112.06K | 0 |
| Total Liabilities | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M |
| Common Stock | 15.97K | 15.97K | 15.97K | 89.7K | 91.88K |
| Retained Earnings | (29.25M) | (44.09M) | (68.05M) | (94.78M) | (130.9M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 48.27M | 34.76M | 11.87M | 95.27M | 60.47M |
| Total Debt | 0 | 55.08K | 0 | 219.38K | 112.06K |
| Net Debt | (49.64M) | (35.44M) | (14.45M) | (94.21M) | (65.88M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.